Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Debt (2021)

Barinthus Biotherapeutics (BRNS) has disclosed Total Debt for 1 consecutive years, with $159000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Total Debt changed N/A year-over-year to $159000.0, compared with a TTM value of $159000.0 through Dec 2021, changed N/A, and an annual FY2021 reading of $159000.0, changed N/A over the prior year.
  • Total Debt was $159000.0 for Q4 2021 at Barinthus Biotherapeutics.
  • Across five years, Total Debt topped out at $159000.0 in Q4 2021 and bottomed at $159000.0 in Q4 2021.